肾透明细胞癌中非转移性黑色素瘤糖蛋白B的表达及临床价值  

Expression of glycoprotein non-metastatic melanoma protein B in clear-cell renal cell carcinoma and clinical implication thereof

作　　者：赫崇军[1] 秦彩朋[1] 徐涛[1] 袁也晴[1] 刘振华[1] 盛正祚 胡风战 顿耀军 王晓峰[1] 

机构地区：[1]北京大学人民医院泌尿外科,100044

出　　处：《中华医学杂志》2015年第30期2455-2458,共4页National Medical Journal of China

摘　　要：目的 探讨非转移性黑色素瘤糖蛋白B（Gpnmb）在肾透明细胞癌中表达及其与预后的相关性.方法 应用免疫组织化学方法检测2009年3月至2012年3月北京大学人民医院诊治的12例肾透明细胞癌患者原发灶组织及对应转移灶中Gpnmb表达的差异.同时检测43例不同阶段肾透明细胞癌患者原发灶中Gpnmb的相对表达量,分析其与肾癌患者年龄、性别、临床分期及病理分级的相关性,并应用Kaplan-Meier法分析Gpnmb表达与肾透明细胞癌患者预后的相关性.结果 Gpnmb在肾透明细胞癌原发灶中的表达水平低于转移灶[（3.14±2.38）比（6.36±4.01）分,P=0.036].肾透明细胞癌患者原发灶中Gpnmb的高表达不受年龄、性别、临床分期和病理分级影响（均P ＞0.05）.Kaplan-Meier分析显示Gpnmb高表达组生存期下降（P=0.020）,比例风险模型显示Gpnmb高表达的患者生存的相对危险度是低表达患者的7.719倍（P =0.049）.结论 肾透明细胞癌患者高表达Gpnmb提示预后不良.Objective To elucidate the glycoprotein non-metastatic melanoma protein B （Gpnmb） expression in clear-cell renal cell carcinoma （ccRCC） and to determine its potential prognostic relevance.Methods A total of 12 pairs of ccRCC tissue specimens were collected from patients undergoing surgery in our hospital from March 2009 to March 2012.Gpnmb expression were determined by immunohistochemistry and correlated with clinical variables.Survival analysis was carried out for another 43 evaluable patients.Results The expression level of Gpnmb was significantly higher in metastatic ccRCCs than that in matched primary samples （（6.36 ± 4.01） vs （3.14 ± 2.38） scores,P =0.036）.The high expression of Gpnmb was not affected by age,gender,clinical stage and pathological grade （all P 〉 0.05）.Kaplan-Meier analysis disclosed significant differences in overall survival for patients with higher and lower average Gpnmb expression levels（P =0.020）.Cox regression analysis revealed that a high Gpnmb protein expression level in the tumor cell could be identified as an independent poor prognostic marker of overall survival in ccRCC patients（P =0.049）.Conclusion Over expression of Gpnmb in tumour cell predicts a poor prognosis of patients with ccRCC.

关 键 词：肾肿瘤 肿瘤转移 肾透明细胞癌 预后 

分 类 号：R737.11[医药卫生—肿瘤]